External broker reports(aggregated public sources), Prabhudas Lilladhar

Prabhudas Lilladhar

External broker reports(aggregated public sources)

Prabhudas Lilladher is one of India's leading research based financial services organisation.

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>We revise our CY25/26E EPS estimates by -2.9%/-6.1% factoring in pricing normalization and transient base order moderation but upgrade the rating to ‘BUY’ from Accumulate due to recent sharp correction in stock price and ABB’s sustained growth momentum.</li><li>ABB India (ABB) reported strong quarterly performance with revenue growing 22.0% YoY and EBITDA margin expanding by 440bps YoY to 19.5%.</li><li>During the quarter, the growth was led by strong momentum in Electrification and execution upticks in Data center orders.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

We revise our CY25/26E EPS estimates by -2.9%/-6.1% factoring in pricing normalization and transient base order moderation but upgrade the rating to ‘BUY’ from Accumulate due to recent sharp correction in stock price and ABB’s sustained growth momentum.ABB India (ABB) reported strong quarterly performance with revenue growing 22.0% YoY and EBITDA margin expanding by 440bps YoY to 19.5%.During the quarter, the growth was led by strong momentum in Electrification and execution upticks in Data center orders.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

ABB India (ABB IN) - Strong Q4; Healthy Outlook Across Key Segments

External broker reports(aggregated public sources), ICICI Securities Ltd

ICICI Securities Limited

ICICI Securities Ltd

ICICI Securities Limited provides investment services. The Company provides corporate and investment banking, securities, wealth management, retail brokerage, initial public offerings, and advisory services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>ABB India (ABB) reported a strong Q4CY24 result with revenue of INR 33.7bn (+22% YoY), EBITDA of INR 6.6bn (+58% YoY) and PAT of INR 5.3bn (+54% YoY).</li><li>EBITDA margin continued its uptrend to 19.5% for the quarter (+440bps YoY).</li><li>Note that revenue grew 19%, 24%, 22% and 17% in CY21, CY22, CY23 and CY24, respectively.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

ABB India (ABB) reported a strong Q4CY24 result with revenue of INR 33.7bn (+22% YoY), EBITDA of INR 6.6bn (+58% YoY) and PAT of INR 5.3bn (+54% YoY).EBITDA margin continued its uptrend to 19.5% for the quarter (+440bps YoY).Note that revenue grew 19%, 24%, 22% and 17% in CY21, CY22, CY23 and CY24, respectively.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

ABB India - A Strong Quarter Marred by Decline in Order Inflow

External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>AIL reported revenue growth of 12.3% YoY in Q3FY25, slightly ahead of expectations of 8% YoY.</li><li>Abbott’s growth of 12.3% outpaced the IPM's growth of 8.0%.</li><li>An increase in secondary sales and a higher share of Duphalac, Udiliv, and Rybelsus, which reported QoQ growth of 17.1%, 19.4%, and 51% respectively, contributed to the improved market share.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

AIL reported revenue growth of 12.3% YoY in Q3FY25, slightly ahead of expectations of 8% YoY.Abbott’s growth of 12.3% outpaced the IPM's growth of 8.0%.An increase in secondary sales and a higher share of Duphalac, Udiliv, and Rybelsus, which reported QoQ growth of 17.1%, 19.4%, and 51% respectively, contributed to the improved market share.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Abbott India Ltd - Outpacing IPM & Sustaining Higher EBITDA Margins

<ul><li>ABB India (ABB) reported muted revenue of INR 29bn, +5% YoY compared to double-digit growth reported in last 14 quarters.</li><li>Note that revenues grew by 19%, 24%, 22% and 20% in CY21, CY22, CY23 and H1CY24 respectively.</li><li>Order inflow for the quarter was INR 34bn, + 11% YoY.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

ABB India (ABB) reported muted revenue of INR 29bn, +5% YoY compared to double-digit growth reported in last 14 quarters.Note that revenues grew by 19%, 24%, 22% and 20% in CY21, CY22, CY23 and H1CY24 respectively.Order inflow for the quarter was INR 34bn, + 11% YoY.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

ABB India - A Sub-Par Revenue and Order Inflow

<ul><li>Abbott India, a leading pharmaceutical company and subsidiary of Abbott Laboratories, focuses on developing and distributing a diverse range of healthcare products across key therapeutic areas, including gastroenterology, women's health, cardiology, CNS, and others.</li><li>Known for its commitment to innovation, the company offers popular brands such as Digene and Thyronorm.</li><li>With a robust distribution network and adherence to high-quality manufacturing standards, Abbott India plays a significant role in improving healthcare outcomes across the country.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Abbott India, a leading pharmaceutical company and subsidiary of Abbott Laboratories, focuses on developing and distributing a diverse range of healthcare products across key therapeutic areas, including gastroenterology, women's health, cardiology, CNS, and others.Known for its commitment to innovation, the company offers popular brands such as Digene and Thyronorm.With a robust distribution network and adherence to high-quality manufacturing standards, Abbott India plays a significant role in improving healthcare outcomes across the country.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pick of the Week: Abbott India Ltd. - 28 October 2024

India

ABB India Limited undertakes engineering and construction projects and manufactures heavy engineering and industrial equipment. The Company undertakes projects in the field of energy production, power transmission, transportation, process automation and pollution control. ABB India's products include pollution control equipment, switch gears and high current rectifiers.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

ABB India Ltd (ABB IN)

ABB India (ABB IN) - Strong Q4; Healthy Outlook Across Key Segments

ABB India (ABB) reported strong quarterly performance with revenue growing 22.0% YoY and EBITDA margin expanding by 440bps YoY to 19.5%.

Prabhudas Lilladhar

ABB India - A Strong Quarter Marred by Decline in Order Inflow

ABB India (ABB) reported a strong Q4CY24 result with revenue of INR 33.7bn (+22% YoY), EBITDA of INR 6.6bn (+58% YoY) and PAT of INR 5.3bn (+54% YoY).

ICICI Securities Limited

Abbott India Ltd - Outpacing IPM & Sustaining Higher EBITDA Margins

AIL reported revenue growth of 12.3% YoY in Q3FY25, slightly ahead of expectations of 8% YoY. Abbott’s growth of 12.3% outpaced the IPM's growth of...

Axis Direct

ABB India - A Sub-Par Revenue and Order Inflow

Note that revenues grew by 19%, 24%, 22% and 20% in CY21, CY22, CY23 and H1CY24 respectively. Order inflow for the quarter was INR 34bn, + 11% YoY.

ICICI Securities Limited

Pick of the Week: Abbott India Ltd. - 28 October 2024

Abbott India, a leading pharmaceutical company and subsidiary of Abbott Laboratories, focuses on developing and distributing a diverse range of...

Axis Direct

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)